Press Releases

Magnify Magazine

Media Resources

Press Releases

microscope

Magnify Magazine

microscope

Media Resources

microscope

Images of charts

 October 6, 2026 ARUP Artificial Intelligence Project Selected for Redtail AI Factory Challenge Project

ARUP’s inclusion in the Redtail AI Factory’s second challenge project cohort will accelerate development of an AI foundation model designed to enhance analysis of clinical flow cytometry data.

Clinician in lab pipettes a test sample.

 September 22, 2026 ARUP Urges Swift Passage of RESULTS Act Following CMS Release of Preliminary PAMA Rates

Proposed cuts to Medicare reimbursements for lab tests released September 21 underscore the urgent need for Congress to pass the bipartisan RESULTS Act to fix flaws in how reimbursement is calculated.

Headshots of Danielle LaGrave, left, Lauren Wallace, and Katie Rudd

ARUP researchers, including (left to right) Danielle LaGrave, MS, LCGC, Lauren Wallace, MS, LCGC, and Katie Rudd, PhD, FACMG, have investigated the connection between atypical cell-free DNA screening results and diagnostic findings. (Not pictured: Rebekah Whitham, BS, MA, and Hannah S. Anderson, MS, LCGC)

 September 8, 2026 Groundbreaking ARUP Research Clarifies Clinical Value of Atypical Cell-Free DNA Screening Results

Atypical cell-free DNA results frequently indicate clinically relevant diagnoses and offer important clues for follow-up diagnostic testing.

Screenshot of dashboard that shows the Cyclospora positivity rates

ARUP Laboratories observed Cyclospora positivity rates increase from very low levels to unprecedented levels within a short period of time, highlighting the importance of providing clinicians and laboratorians with timely disease surveillance data, said Ben Bradley, MD, PhD, ARUP head of clinical operations for Infectious Disease.

 August 3, 2026 ARUP Laboratories Adds Cyclospora Data to Infectious Disease Dashboard Amid National Outbreak

ARUP Laboratories’ Infectious Disease Test Positivity Trends Dashboard now includes Cyclospora data to help clinicians and public health professionals monitor the rising cyclosporiasis outbreak.

Image of small neoplastic populations

ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes small neoplastic populations with greater sensitivity than conventional flow cytometry while requiring less specimen volume.

 July 20, 2026 ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple Myeloma

ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry characterizes neoplastic populations with greater confidence and sensitivity, while minimizing specimen volume requirements.

Text text text

Jonathan Genzen, MD, PhD, MBA, ARUP’s chief medical officer and senior director of governmental affairs, said the Enhancing CLIA Act is an intriguing step forward in considering future oversight of laboratory-developed tests.

 June 16, 2026 Clinical Labs Review Proposed Legislation To Modernize Oversight of Lab-Developed Tests Under CLIA

Newly introduced federal legislation would modernize oversight of lab-developed tests under the Clinical Laboratory Improvement Amendments but support innovation, transparency, and patient access.